Hennepin Life Sciences is a growth-stage human and animal health company that is uniquely focused on the development of patent protected, novel, naturally-derived anti-infective compounds for the prevention and treatment of a wide array of infections. We created innovative nature-based therapies by combining molecular concepts of infection to clinical applications. Founded in 2009 from a technology transfer out of the University of Minnesota, Hennepin Life Sciences (HLS) is a Minnesota-based biotechnology firm in its clinical trial stage, developing a patented approach to address the global super bug challenge. Today, HLS continues to expand its product platform and intellectual property, advance the practical science through clinical studies, and forge distribution partnerships to reach clinical application. A spectrum solution is highly relevant for the superbug era we live in, and has broad applicability in the human and animal health markets. Studies thus far have shown the HLS approach to safely kill bacteria, fungus, and viruses while nearly eliminating bacterial mutations. HLS believes initial findings validate application in broad markets, such as the highly scrutinized hospital acquired infection (HAI) market and the more defined and rapidly growing women's health category.